Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis

Erika F. Rodriguez, Maryam Shabihkhani, Jamal H. Carter, Zahra Maleki

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: The aim of this study was to report cytologic and molecular features of pulmonary adenocarcinoma patients presenting with a malignant pleural effusion at the first diagnosis. Study Design: Patients who had a cytopathologic diagnosis conclusive for lung adenocarcinoma for the first time on their pleural fluid specimen, and molecular testing done, were studied. The control group consisted of patients with a malignant pleural effusion that developed during disease progression. Results: We identified 18 patients (9 males and 9 females). Micropapillary and/or solid adenocarcinoma type features predominated among cytologic specimens (n = 15), while acinar patterns predominated in controls. Survival was not significantly different from that of the control group (mean 13.8 vs. 13.9 months, respectively; p = 0.61). Ten (55%) cases had mutations in EGFR (n = 6; 60%), KRAS (n = 3; 30%), or ALK translocation (n = 1; 10%). No mutations were identified in BRAF, AKT, ERBB2, NRAS, or PIK3CA (tested in 7 patients). Patients positive for the tested mutations had a better overall survival than patients negative for the mutations (mean survival 16.2 vs. 6.05 months, respectively; p = 0.006, log-rank test). Ten (84%) control patients were positive for mutations in EGFR (n = 5; 42%), KRAS (n = 4; 34%), or ALK translocation (n = 1; 8.4%). Conclusion: In our series, a micropapillary-like and solid-like morphology, common in cytologic specimens, and alterations in EGFR were the most frequent identifiable molecular changes.

Original languageEnglish (US)
Pages (from-to)214-222
Number of pages9
JournalActa Cytologica
Volume61
Issue number3
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Mutation
Survival
Control Groups
Adenocarcinoma of lung
Disease Progression
Adenocarcinoma

Keywords

  • Malignant pleural effusion
  • Metastatic pulmonary adenocarcinoma
  • Molecular changes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis. / Rodriguez, Erika F.; Shabihkhani, Maryam; Carter, Jamal H.; Maleki, Zahra.

In: Acta Cytologica, Vol. 61, No. 3, 01.06.2017, p. 214-222.

Research output: Contribution to journalArticle

@article{1e0289c5a1be4dd5b5c3e2fa3fb819db,
title = "Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis",
abstract = "Objectives: The aim of this study was to report cytologic and molecular features of pulmonary adenocarcinoma patients presenting with a malignant pleural effusion at the first diagnosis. Study Design: Patients who had a cytopathologic diagnosis conclusive for lung adenocarcinoma for the first time on their pleural fluid specimen, and molecular testing done, were studied. The control group consisted of patients with a malignant pleural effusion that developed during disease progression. Results: We identified 18 patients (9 males and 9 females). Micropapillary and/or solid adenocarcinoma type features predominated among cytologic specimens (n = 15), while acinar patterns predominated in controls. Survival was not significantly different from that of the control group (mean 13.8 vs. 13.9 months, respectively; p = 0.61). Ten (55{\%}) cases had mutations in EGFR (n = 6; 60{\%}), KRAS (n = 3; 30{\%}), or ALK translocation (n = 1; 10{\%}). No mutations were identified in BRAF, AKT, ERBB2, NRAS, or PIK3CA (tested in 7 patients). Patients positive for the tested mutations had a better overall survival than patients negative for the mutations (mean survival 16.2 vs. 6.05 months, respectively; p = 0.006, log-rank test). Ten (84{\%}) control patients were positive for mutations in EGFR (n = 5; 42{\%}), KRAS (n = 4; 34{\%}), or ALK translocation (n = 1; 8.4{\%}). Conclusion: In our series, a micropapillary-like and solid-like morphology, common in cytologic specimens, and alterations in EGFR were the most frequent identifiable molecular changes.",
keywords = "Malignant pleural effusion, Metastatic pulmonary adenocarcinoma, Molecular changes",
author = "Rodriguez, {Erika F.} and Maryam Shabihkhani and Carter, {Jamal H.} and Zahra Maleki",
year = "2017",
month = "6",
day = "1",
doi = "10.1159/000477148",
language = "English (US)",
volume = "61",
pages = "214--222",
journal = "Acta Cytologica",
issn = "0001-5547",
publisher = "Science Printers and Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis

AU - Rodriguez, Erika F.

AU - Shabihkhani, Maryam

AU - Carter, Jamal H.

AU - Maleki, Zahra

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objectives: The aim of this study was to report cytologic and molecular features of pulmonary adenocarcinoma patients presenting with a malignant pleural effusion at the first diagnosis. Study Design: Patients who had a cytopathologic diagnosis conclusive for lung adenocarcinoma for the first time on their pleural fluid specimen, and molecular testing done, were studied. The control group consisted of patients with a malignant pleural effusion that developed during disease progression. Results: We identified 18 patients (9 males and 9 females). Micropapillary and/or solid adenocarcinoma type features predominated among cytologic specimens (n = 15), while acinar patterns predominated in controls. Survival was not significantly different from that of the control group (mean 13.8 vs. 13.9 months, respectively; p = 0.61). Ten (55%) cases had mutations in EGFR (n = 6; 60%), KRAS (n = 3; 30%), or ALK translocation (n = 1; 10%). No mutations were identified in BRAF, AKT, ERBB2, NRAS, or PIK3CA (tested in 7 patients). Patients positive for the tested mutations had a better overall survival than patients negative for the mutations (mean survival 16.2 vs. 6.05 months, respectively; p = 0.006, log-rank test). Ten (84%) control patients were positive for mutations in EGFR (n = 5; 42%), KRAS (n = 4; 34%), or ALK translocation (n = 1; 8.4%). Conclusion: In our series, a micropapillary-like and solid-like morphology, common in cytologic specimens, and alterations in EGFR were the most frequent identifiable molecular changes.

AB - Objectives: The aim of this study was to report cytologic and molecular features of pulmonary adenocarcinoma patients presenting with a malignant pleural effusion at the first diagnosis. Study Design: Patients who had a cytopathologic diagnosis conclusive for lung adenocarcinoma for the first time on their pleural fluid specimen, and molecular testing done, were studied. The control group consisted of patients with a malignant pleural effusion that developed during disease progression. Results: We identified 18 patients (9 males and 9 females). Micropapillary and/or solid adenocarcinoma type features predominated among cytologic specimens (n = 15), while acinar patterns predominated in controls. Survival was not significantly different from that of the control group (mean 13.8 vs. 13.9 months, respectively; p = 0.61). Ten (55%) cases had mutations in EGFR (n = 6; 60%), KRAS (n = 3; 30%), or ALK translocation (n = 1; 10%). No mutations were identified in BRAF, AKT, ERBB2, NRAS, or PIK3CA (tested in 7 patients). Patients positive for the tested mutations had a better overall survival than patients negative for the mutations (mean survival 16.2 vs. 6.05 months, respectively; p = 0.006, log-rank test). Ten (84%) control patients were positive for mutations in EGFR (n = 5; 42%), KRAS (n = 4; 34%), or ALK translocation (n = 1; 8.4%). Conclusion: In our series, a micropapillary-like and solid-like morphology, common in cytologic specimens, and alterations in EGFR were the most frequent identifiable molecular changes.

KW - Malignant pleural effusion

KW - Metastatic pulmonary adenocarcinoma

KW - Molecular changes

UR - http://www.scopus.com/inward/record.url?scp=85020170580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020170580&partnerID=8YFLogxK

U2 - 10.1159/000477148

DO - 10.1159/000477148

M3 - Article

C2 - 28538219

AN - SCOPUS:85020170580

VL - 61

SP - 214

EP - 222

JO - Acta Cytologica

JF - Acta Cytologica

SN - 0001-5547

IS - 3

ER -